Nebula Research & Development’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Nebula Research & Development’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-31,781	Closed	-$2.65M	–	1185
2024 Q4	$2.65M	Buy	31,781 +9,740	+44%	+$800K	0.31%	64
2024 Q3	$1.61M	Sell	22,041 -11,631	-35%	-$874K	0.19%	137
2024 Q2	$2.31M	Buy	+33,672	New	+$2.34M	0.37%	32
2024 Q1	–	Sell	-8,631	Closed	-$618K	–	1033
2023 Q4	$618K	Buy	8,631 +2,166	+34%	+$125K	0.19%	184
2023 Q3	$337K	Buy	+6,465	New	+$377K	0.18%	240
2023 Q2	–	Sell	-3,960	Closed	-$214K	–	465
2023 Q1	$214K	Buy	+3,960	New	+$191K	0.38%	167

Other funds holding ITCI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Nebula Research & Development's ITCI Position: Q1 2025 in Review

Nebula Research & Development sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 31,781 shares — an estimated $2.65M sold.

Nebula Research & Development first reported a position in ITCI in Q1 2023 and held it in 6 quarters. The position peaked at $2.65M in Q4 2024. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

Nebula Research & Development reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
Nebula Research & Development sold 31,781 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $2.65M.
Nebula Research & Development first reported a position in Intra-Cellular Therapies Inc. in Q1 2023 and held it in 6 quarters.
Nebula Research & Development's Intra-Cellular Therapies Inc. position peaked at $2.65M in Q4 2024.
395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on Nebula Research & Development's 13F filing for Q1 2025, filed 15 May 2025.